We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.17 | 0.13% | 131.90 | 1,699 | 13:14:17 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said the Food and Drug Administration accepted a supplemental Biologics License Application for its Keytruda cancer drug as adjuvant therapy in patients with resected, high-risk stage III melanoma, the most serious form of skin cancer.
The Kenilworth, N.J., drug maker said the sBLA is based on a significant benefit in recurrence-free survival shown by Keytruda in a pivotal Phase 3 trial.
Keytruda, a new type of cancer drug that harnesses patients' immune systems to fight tumors, is already marketed to treat lung, skin, bladder and other cancers.
Merck said the FDA set a target action date of Feb. 16, 2019 for the sBLA.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 25, 2018 07:06 ET (11:06 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
